SMARCA4 and neoplasm: As a tumor suppressor aberrantly expressed in approximately 10% of NSCLC, SMARCA4-DNSCLC exhibits a unique combination of histomorphological, immunophenotypic, and molecular genetic attributes with weak response to conventional chemotherapy and poor prognosis (5).